European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Refresher training webinar on post-authorisation procedure management in IRIS for marketing authorisation holders, Online, European Medicines Agency, Amsterdam, the Netherlands, from 30 September 2025, 10:00 (CEST) to 30 September 2025, 12:00 (CEST)

Submitted by Anonymous (not verified) on 2 October 2025 - 15:27

Refresher training webinar on post-authorisation procedure management in IRIS for marketing authorisation holders, Online, European Medicines Agency, Amsterdam, the Netherlands, from 30 September 2025, 10:00 (CEST) to 30 September 2025, 12:00 (CEST)

Human medicines European public assessment report (EPAR): Tremfya, guselkumab, Date of authorisation: 10/11/2017, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 2 October 2025 - 15:25

Human medicines European public assessment report (EPAR): Tremfya, guselkumab, Date of authorisation: 10/11/2017, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Elahere, mirvetuximab soravtansine, Date of authorisation: 14/11/2024, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 2 October 2025 - 15:22

Human medicines European public assessment report (EPAR): Elahere, mirvetuximab soravtansine, Date of authorisation: 14/11/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Tyenne, tocilizumab, Date of authorisation: 15/09/2023, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 2 October 2025 - 15:20

Human medicines European public assessment report (EPAR): Tyenne, tocilizumab, Date of authorisation: 15/09/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 3, Status: Authorised

Submitted by Anonymous (not verified) on 2 October 2025 - 15:05

Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 3, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More